COVID-19 Should Force ‘Soul Searching’ Over Fragmented US Clinical Trials System, Woodcock Says
Executive Summary
Among hundreds of trials underway on potential therapeutics, only about 6% of study arms are expected to yield actionable data because most are nonrandomized, underpowered or underenrolled, Operation Warp Speed’s Janet Woodcock says, renewing her pitch for adoption of master protocols and other approaches to streamline studies and improve efficiency.
You may also be interested in...
Full Extent Of Clinical Trial Damage May Be Unknown Until Pandemic Ends, CBER’s Peter Marks Says
More patient-centric trial designs also may be coming due to pandemic-related advances, Marks says.
Lilly’s EUA Timeline For COVID-19 Combo Antibody Depends On Safety Data, Manufacturing
Single neutralizing antibody moves to US FDA with data showing reduced hospitalization, while Lilly’s EUA filing for two-antibody combo awaits safety data and more certainty about production capabilities.
ACTIV Picks Potential COVID-19 Therapeutics To Be Tested In Master Protocol Trials
Three host-targeted immune modulators, three anticoagulants, and three to six neutralizing antibodies are to be tested in ACTIV clinical trials, FNIH's David Wholley tells DIA meeting.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: